Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives $3.92 Consensus Price Target from Brokerages

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have been given a consensus recommendation of “Hold” by the ten ratings firms that are currently covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $3.92.

Separately, Wall Street Zen assumed coverage on Marinus Pharmaceuticals in a report on Wednesday, May 21st. They issued a “sell” rating on the stock.

Marinus Pharmaceuticals Trading Down 0.2%

Shares of Marinus Pharmaceuticals stock opened at $0.55 on Wednesday. Marinus Pharmaceuticals has a 52 week low of $0.22 and a 52 week high of $1.97. The stock has a market cap of $30.32 million, a PE ratio of -0.22 and a beta of 1.03. The company’s 50-day moving average price is $0.55 and its two-hundred day moving average price is $0.53.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Several hedge funds have recently made changes to their positions in MRNS. Virtu Financial LLC purchased a new position in Marinus Pharmaceuticals during the 4th quarter worth approximately $36,000. XTX Topco Ltd boosted its position in shares of Marinus Pharmaceuticals by 1,564.7% in the fourth quarter. XTX Topco Ltd now owns 219,819 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 206,614 shares during the period. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new position in shares of Marinus Pharmaceuticals during the fourth quarter valued at $54,000. Beryl Capital Management LLC purchased a new position in shares of Marinus Pharmaceuticals during the fourth quarter valued at $2,262,000. Finally, JPMorgan Chase & Co. raised its position in Marinus Pharmaceuticals by 266.1% during the fourth quarter. JPMorgan Chase & Co. now owns 487,584 shares of the biopharmaceutical company’s stock valued at $261,000 after buying an additional 354,393 shares during the period. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.